Global Patient Derived Xenograft & PDX Models Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Patient Derived Xenograft & PDX Models Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 100

Published Date: 02 Jan 2023

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

  • sp_icon1 sp_icon1_b Description
  • sp_icon2 sp_icon2_b Table of Contents
  • sp_icon3 sp_icon3_b Table of Figures
  • sp_icon4 sp_icon4_b Research Methodology
  • sp_icon1 sp_icon1_b Companies Mentioned
  • sp_icon1 sp_icon1_b Related Reports
  • sp_icon1 sp_icon1_b Product Tags
btl

Description

Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. PDX models are used to create an environment that allows for the natural growth of cancer, its monitoring, and corresponding treatment evaluations for the original patient.

According to our (Global Info Research) latest study, the global Patient Derived Xenograft & PDX Models market size was valued at USD 341.2 million in 2022 and is forecast to a readjusted size of USD 589.9 million by 2029 with a CAGR of 8.1% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.

This report is a detailed and comprehensive analysis for global Patient Derived Xenograft & PDX Models market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Patient Derived Xenograft & PDX Models market size and forecasts, in consumption value ($ Million), 2018-2029
Global Patient Derived Xenograft & PDX Models market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Patient Derived Xenograft & PDX Models market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Patient Derived Xenograft & PDX Models market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Patient Derived Xenograft & PDX Models
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Patient Derived Xenograft & PDX Models market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Crown Bioscience, The Jackson Laboratory, Champions Oncology, Charles River Laboratories and WuXi Apptec, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Patient Derived Xenograft & PDX Models market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Mice Models
Rat Models

Market segment by Application
Pre-clinical Drug Development and Basic Cancer Research
Biomarker Analysis

Market segment by players, this report covers
Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Patient Derived Xenograft & PDX Models product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Patient Derived Xenograft & PDX Models, with revenue, gross margin and global market share of Patient Derived Xenograft & PDX Models from 2018 to 2023.
Chapter 3, the Patient Derived Xenograft & PDX Models competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Patient Derived Xenograft & PDX Models market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Patient Derived Xenograft & PDX Models.
Chapter 13, to describe Patient Derived Xenograft & PDX Models research findings and conclusion.
btl

Table of Contents

1 Market Overview
1.1 Product Overview and Scope of Patient Derived Xenograft & PDX Models
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Patient Derived Xenograft & PDX Models by Type
1.3.1 Overview: Global Patient Derived Xenograft & PDX Models Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Patient Derived Xenograft & PDX Models Consumption Value Market Share by Type in 2022
1.3.3 Mice Models
1.3.4 Rat Models
1.4 Global Patient Derived Xenograft & PDX Models Market by Application
1.4.1 Overview: Global Patient Derived Xenograft & PDX Models Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Pre-clinical Drug Development and Basic Cancer Research
1.4.3 Biomarker Analysis
1.5 Global Patient Derived Xenograft & PDX Models Market Size & Forecast
1.6 Global Patient Derived Xenograft & PDX Models Market Size and Forecast by Region
1.6.1 Global Patient Derived Xenograft & PDX Models Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Patient Derived Xenograft & PDX Models Market Size by Region, (2018-2029)
1.6.3 North America Patient Derived Xenograft & PDX Models Market Size and Prospect (2018-2029)
1.6.4 Europe Patient Derived Xenograft & PDX Models Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Patient Derived Xenograft & PDX Models Market Size and Prospect (2018-2029)
1.6.6 South America Patient Derived Xenograft & PDX Models Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Patient Derived Xenograft & PDX Models Market Size and Prospect (2018-2029)

2 Company Profiles
2.1 Crown Bioscience
2.1.1 Crown Bioscience Details
2.1.2 Crown Bioscience Major Business
2.1.3 Crown Bioscience Patient Derived Xenograft & PDX Models Product and Solutions
2.1.4 Crown Bioscience Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Crown Bioscience Recent Developments and Future Plans
2.2 The Jackson Laboratory
2.2.1 The Jackson Laboratory Details
2.2.2 The Jackson Laboratory Major Business
2.2.3 The Jackson Laboratory Patient Derived Xenograft & PDX Models Product and Solutions
2.2.4 The Jackson Laboratory Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 The Jackson Laboratory Recent Developments and Future Plans
2.3 Champions Oncology
2.3.1 Champions Oncology Details
2.3.2 Champions Oncology Major Business
2.3.3 Champions Oncology Patient Derived Xenograft & PDX Models Product and Solutions
2.3.4 Champions Oncology Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Champions Oncology Recent Developments and Future Plans
2.4 Charles River Laboratories
2.4.1 Charles River Laboratories Details
2.4.2 Charles River Laboratories Major Business
2.4.3 Charles River Laboratories Patient Derived Xenograft & PDX Models Product and Solutions
2.4.4 Charles River Laboratories Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Charles River Laboratories Recent Developments and Future Plans
2.5 WuXi Apptec
2.5.1 WuXi Apptec Details
2.5.2 WuXi Apptec Major Business
2.5.3 WuXi Apptec Patient Derived Xenograft & PDX Models Product and Solutions
2.5.4 WuXi Apptec Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 WuXi Apptec Recent Developments and Future Plans
2.6 Oncodesign
2.6.1 Oncodesign Details
2.6.2 Oncodesign Major Business
2.6.3 Oncodesign Patient Derived Xenograft & PDX Models Product and Solutions
2.6.4 Oncodesign Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Oncodesign Recent Developments and Future Plans
2.7 Horizon Discovery
2.7.1 Horizon Discovery Details
2.7.2 Horizon Discovery Major Business
2.7.3 Horizon Discovery Patient Derived Xenograft & PDX Models Product and Solutions
2.7.4 Horizon Discovery Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Horizon Discovery Recent Developments and Future Plans
2.8 Pharmatest Services
2.8.1 Pharmatest Services Details
2.8.2 Pharmatest Services Major Business
2.8.3 Pharmatest Services Patient Derived Xenograft & PDX Models Product and Solutions
2.8.4 Pharmatest Services Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Pharmatest Services Recent Developments and Future Plans
2.9 Hera Biolabs
2.9.1 Hera Biolabs Details
2.9.2 Hera Biolabs Major Business
2.9.3 Hera Biolabs Patient Derived Xenograft & PDX Models Product and Solutions
2.9.4 Hera Biolabs Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Hera Biolabs Recent Developments and Future Plans
2.10 EPO Berlin-Buch
2.10.1 EPO Berlin-Buch Details
2.10.2 EPO Berlin-Buch Major Business
2.10.3 EPO Berlin-Buch Patient Derived Xenograft & PDX Models Product and Solutions
2.10.4 EPO Berlin-Buch Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 EPO Berlin-Buch Recent Developments and Future Plans
2.11 Xentech
2.11.1 Xentech Details
2.11.2 Xentech Major Business
2.11.3 Xentech Patient Derived Xenograft & PDX Models Product and Solutions
2.11.4 Xentech Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Xentech Recent Developments and Future Plans
2.12 Urolead
2.12.1 Urolead Details
2.12.2 Urolead Major Business
2.12.3 Urolead Patient Derived Xenograft & PDX Models Product and Solutions
2.12.4 Urolead Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Urolead Recent Developments and Future Plans

3 Market Competition, by Players
3.1 Global Patient Derived Xenograft & PDX Models Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Patient Derived Xenograft & PDX Models by Company Revenue
3.2.2 Top 3 Patient Derived Xenograft & PDX Models Players Market Share in 2022
3.2.3 Top 6 Patient Derived Xenograft & PDX Models Players Market Share in 2022
3.3 Patient Derived Xenograft & PDX Models Market: Overall Company Footprint Analysis
3.3.1 Patient Derived Xenograft & PDX Models Market: Region Footprint
3.3.2 Patient Derived Xenograft & PDX Models Market: Company Product Type Footprint
3.3.3 Patient Derived Xenograft & PDX Models Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
4.1 Global Patient Derived Xenograft & PDX Models Consumption Value and Market Share by Type (2018-2023)
4.2 Global Patient Derived Xenograft & PDX Models Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
5.1 Global Patient Derived Xenograft & PDX Models Consumption Value Market Share by Application (2018-2023)
5.2 Global Patient Derived Xenograft & PDX Models Market Forecast by Application (2024-2029)

6 North America
6.1 North America Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2029)
6.2 North America Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2029)
6.3 North America Patient Derived Xenograft & PDX Models Market Size by Country
6.3.1 North America Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2029)
6.3.2 United States Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
6.3.3 Canada Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
6.3.4 Mexico Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)

7 Europe
7.1 Europe Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2029)
7.2 Europe Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2029)
7.3 Europe Patient Derived Xenograft & PDX Models Market Size by Country
7.3.1 Europe Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2029)
7.3.2 Germany Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
7.3.3 France Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
7.3.5 Russia Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
7.3.6 Italy Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)

8 Asia-Pacific
8.1 Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Patient Derived Xenograft & PDX Models Market Size by Region
8.3.1 Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Region (2018-2029)
8.3.2 China Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
8.3.3 Japan Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
8.3.4 South Korea Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
8.3.5 India Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
8.3.7 Australia Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)

9 South America
9.1 South America Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2029)
9.2 South America Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2029)
9.3 South America Patient Derived Xenograft & PDX Models Market Size by Country
9.3.1 South America Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2029)
9.3.2 Brazil Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
9.3.3 Argentina Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)

10 Middle East & Africa
10.1 Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Patient Derived Xenograft & PDX Models Market Size by Country
10.3.1 Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2029)
10.3.2 Turkey Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
10.3.4 UAE Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)

11 Market Dynamics
11.1 Patient Derived Xenograft & PDX Models Market Drivers
11.2 Patient Derived Xenograft & PDX Models Market Restraints
11.3 Patient Derived Xenograft & PDX Models Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
12.1 Patient Derived Xenograft & PDX Models Industry Chain
12.2 Patient Derived Xenograft & PDX Models Upstream Analysis
12.3 Patient Derived Xenograft & PDX Models Midstream Analysis
12.4 Patient Derived Xenograft & PDX Models Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. Global Patient Derived Xenograft & PDX Models Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Patient Derived Xenograft & PDX Models Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Patient Derived Xenograft & PDX Models Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Patient Derived Xenograft & PDX Models Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Crown Bioscience Company Information, Head Office, and Major Competitors
Table 6. Crown Bioscience Major Business
Table 7. Crown Bioscience Patient Derived Xenograft & PDX Models Product and Solutions
Table 8. Crown Bioscience Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Crown Bioscience Recent Developments and Future Plans
Table 10. The Jackson Laboratory Company Information, Head Office, and Major Competitors
Table 11. The Jackson Laboratory Major Business
Table 12. The Jackson Laboratory Patient Derived Xenograft & PDX Models Product and Solutions
Table 13. The Jackson Laboratory Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. The Jackson Laboratory Recent Developments and Future Plans
Table 15. Champions Oncology Company Information, Head Office, and Major Competitors
Table 16. Champions Oncology Major Business
Table 17. Champions Oncology Patient Derived Xenograft & PDX Models Product and Solutions
Table 18. Champions Oncology Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Champions Oncology Recent Developments and Future Plans
Table 20. Charles River Laboratories Company Information, Head Office, and Major Competitors
Table 21. Charles River Laboratories Major Business
Table 22. Charles River Laboratories Patient Derived Xenograft & PDX Models Product and Solutions
Table 23. Charles River Laboratories Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Charles River Laboratories Recent Developments and Future Plans
Table 25. WuXi Apptec Company Information, Head Office, and Major Competitors
Table 26. WuXi Apptec Major Business
Table 27. WuXi Apptec Patient Derived Xenograft & PDX Models Product and Solutions
Table 28. WuXi Apptec Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. WuXi Apptec Recent Developments and Future Plans
Table 30. Oncodesign Company Information, Head Office, and Major Competitors
Table 31. Oncodesign Major Business
Table 32. Oncodesign Patient Derived Xenograft & PDX Models Product and Solutions
Table 33. Oncodesign Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Oncodesign Recent Developments and Future Plans
Table 35. Horizon Discovery Company Information, Head Office, and Major Competitors
Table 36. Horizon Discovery Major Business
Table 37. Horizon Discovery Patient Derived Xenograft & PDX Models Product and Solutions
Table 38. Horizon Discovery Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Horizon Discovery Recent Developments and Future Plans
Table 40. Pharmatest Services Company Information, Head Office, and Major Competitors
Table 41. Pharmatest Services Major Business
Table 42. Pharmatest Services Patient Derived Xenograft & PDX Models Product and Solutions
Table 43. Pharmatest Services Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Pharmatest Services Recent Developments and Future Plans
Table 45. Hera Biolabs Company Information, Head Office, and Major Competitors
Table 46. Hera Biolabs Major Business
Table 47. Hera Biolabs Patient Derived Xenograft & PDX Models Product and Solutions
Table 48. Hera Biolabs Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Hera Biolabs Recent Developments and Future Plans
Table 50. EPO Berlin-Buch Company Information, Head Office, and Major Competitors
Table 51. EPO Berlin-Buch Major Business
Table 52. EPO Berlin-Buch Patient Derived Xenograft & PDX Models Product and Solutions
Table 53. EPO Berlin-Buch Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. EPO Berlin-Buch Recent Developments and Future Plans
Table 55. Xentech Company Information, Head Office, and Major Competitors
Table 56. Xentech Major Business
Table 57. Xentech Patient Derived Xenograft & PDX Models Product and Solutions
Table 58. Xentech Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Xentech Recent Developments and Future Plans
Table 60. Urolead Company Information, Head Office, and Major Competitors
Table 61. Urolead Major Business
Table 62. Urolead Patient Derived Xenograft & PDX Models Product and Solutions
Table 63. Urolead Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Urolead Recent Developments and Future Plans
Table 65. Global Patient Derived Xenograft & PDX Models Revenue (USD Million) by Players (2018-2023)
Table 66. Global Patient Derived Xenograft & PDX Models Revenue Share by Players (2018-2023)
Table 67. Breakdown of Patient Derived Xenograft & PDX Models by Company Type (Tier 1, Tier 2, and Tier 3)
Table 68. Market Position of Players in Patient Derived Xenograft & PDX Models, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 69. Head Office of Key Patient Derived Xenograft & PDX Models Players
Table 70. Patient Derived Xenograft & PDX Models Market: Company Product Type Footprint
Table 71. Patient Derived Xenograft & PDX Models Market: Company Product Application Footprint
Table 72. Patient Derived Xenograft & PDX Models New Market Entrants and Barriers to Market Entry
Table 73. Patient Derived Xenograft & PDX Models Mergers, Acquisition, Agreements, and Collaborations
Table 74. Global Patient Derived Xenograft & PDX Models Consumption Value (USD Million) by Type (2018-2023)
Table 75. Global Patient Derived Xenograft & PDX Models Consumption Value Share by Type (2018-2023)
Table 76. Global Patient Derived Xenograft & PDX Models Consumption Value Forecast by Type (2024-2029)
Table 77. Global Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2023)
Table 78. Global Patient Derived Xenograft & PDX Models Consumption Value Forecast by Application (2024-2029)
Table 79. North America Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2023) & (USD Million)
Table 80. North America Patient Derived Xenograft & PDX Models Consumption Value by Type (2024-2029) & (USD Million)
Table 81. North America Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2023) & (USD Million)
Table 82. North America Patient Derived Xenograft & PDX Models Consumption Value by Application (2024-2029) & (USD Million)
Table 83. North America Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2023) & (USD Million)
Table 84. North America Patient Derived Xenograft & PDX Models Consumption Value by Country (2024-2029) & (USD Million)
Table 85. Europe Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2023) & (USD Million)
Table 86. Europe Patient Derived Xenograft & PDX Models Consumption Value by Type (2024-2029) & (USD Million)
Table 87. Europe Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2023) & (USD Million)
Table 88. Europe Patient Derived Xenograft & PDX Models Consumption Value by Application (2024-2029) & (USD Million)
Table 89. Europe Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Patient Derived Xenograft & PDX Models Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2023) & (USD Million)
Table 92. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Type (2024-2029) & (USD Million)
Table 93. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2023) & (USD Million)
Table 94. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Application (2024-2029) & (USD Million)
Table 95. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Region (2018-2023) & (USD Million)
Table 96. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Region (2024-2029) & (USD Million)
Table 97. South America Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2023) & (USD Million)
Table 98. South America Patient Derived Xenograft & PDX Models Consumption Value by Type (2024-2029) & (USD Million)
Table 99. South America Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2023) & (USD Million)
Table 100. South America Patient Derived Xenograft & PDX Models Consumption Value by Application (2024-2029) & (USD Million)
Table 101. South America Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2023) & (USD Million)
Table 102. South America Patient Derived Xenograft & PDX Models Consumption Value by Country (2024-2029) & (USD Million)
Table 103. Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2023) & (USD Million)
Table 104. Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Type (2024-2029) & (USD Million)
Table 105. Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2023) & (USD Million)
Table 106. Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Application (2024-2029) & (USD Million)
Table 107. Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2023) & (USD Million)
Table 108. Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Country (2024-2029) & (USD Million)
Table 109. Patient Derived Xenograft & PDX Models Raw Material
Table 110. Key Suppliers of Patient Derived Xenograft & PDX Models Raw Materials
List of Figures
Figure 1. Patient Derived Xenograft & PDX Models Picture
Figure 2. Global Patient Derived Xenograft & PDX Models Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Patient Derived Xenograft & PDX Models Consumption Value Market Share by Type in 2022
Figure 4. Mice Models
Figure 5. Rat Models
Figure 6. Global Patient Derived Xenograft & PDX Models Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Patient Derived Xenograft & PDX Models Consumption Value Market Share by Application in 2022
Figure 8. Pre-clinical Drug Development and Basic Cancer Research Picture
Figure 9. Biomarker Analysis Picture
Figure 10. Global Patient Derived Xenograft & PDX Models Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Patient Derived Xenograft & PDX Models Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Market Patient Derived Xenograft & PDX Models Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 13. Global Patient Derived Xenograft & PDX Models Consumption Value Market Share by Region (2018-2029)
Figure 14. Global Patient Derived Xenograft & PDX Models Consumption Value Market Share by Region in 2022
Figure 15. North America Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 16. Europe Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 17. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 18. South America Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 19. Middle East and Africa Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 20. Global Patient Derived Xenograft & PDX Models Revenue Share by Players in 2022
Figure 21. Patient Derived Xenograft & PDX Models Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 22. Global Top 3 Players Patient Derived Xenograft & PDX Models Market Share in 2022
Figure 23. Global Top 6 Players Patient Derived Xenograft & PDX Models Market Share in 2022
Figure 24. Global Patient Derived Xenograft & PDX Models Consumption Value Share by Type (2018-2023)
Figure 25. Global Patient Derived Xenograft & PDX Models Market Share Forecast by Type (2024-2029)
Figure 26. Global Patient Derived Xenograft & PDX Models Consumption Value Share by Application (2018-2023)
Figure 27. Global Patient Derived Xenograft & PDX Models Market Share Forecast by Application (2024-2029)
Figure 28. North America Patient Derived Xenograft & PDX Models Consumption Value Market Share by Type (2018-2029)
Figure 29. North America Patient Derived Xenograft & PDX Models Consumption Value Market Share by Application (2018-2029)
Figure 30. North America Patient Derived Xenograft & PDX Models Consumption Value Market Share by Country (2018-2029)
Figure 31. United States Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 32. Canada Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 33. Mexico Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 34. Europe Patient Derived Xenograft & PDX Models Consumption Value Market Share by Type (2018-2029)
Figure 35. Europe Patient Derived Xenograft & PDX Models Consumption Value Market Share by Application (2018-2029)
Figure 36. Europe Patient Derived Xenograft & PDX Models Consumption Value Market Share by Country (2018-2029)
Figure 37. Germany Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 38. France Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 39. United Kingdom Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 40. Russia Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 41. Italy Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 42. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value Market Share by Type (2018-2029)
Figure 43. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value Market Share by Application (2018-2029)
Figure 44. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value Market Share by Region (2018-2029)
Figure 45. China Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 46. Japan Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 47. South Korea Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 48. India Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 49. Southeast Asia Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 50. Australia Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 51. South America Patient Derived Xenograft & PDX Models Consumption Value Market Share by Type (2018-2029)
Figure 52. South America Patient Derived Xenograft & PDX Models Consumption Value Market Share by Application (2018-2029)
Figure 53. South America Patient Derived Xenograft & PDX Models Consumption Value Market Share by Country (2018-2029)
Figure 54. Brazil Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 55. Argentina Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 56. Middle East and Africa Patient Derived Xenograft & PDX Models Consumption Value Market Share by Type (2018-2029)
Figure 57. Middle East and Africa Patient Derived Xenograft & PDX Models Consumption Value Market Share by Application (2018-2029)
Figure 58. Middle East and Africa Patient Derived Xenograft & PDX Models Consumption Value Market Share by Country (2018-2029)
Figure 59. Turkey Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 60. Saudi Arabia Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 61. UAE Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 62. Patient Derived Xenograft & PDX Models Market Drivers
Figure 63. Patient Derived Xenograft & PDX Models Market Restraints
Figure 64. Patient Derived Xenograft & PDX Models Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Patient Derived Xenograft & PDX Models in 2022
Figure 67. Manufacturing Process Analysis of Patient Derived Xenograft & PDX Models
Figure 68. Patient Derived Xenograft & PDX Models Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

btl

Companies Mentioned

Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead
shop_t

Purchase Options

jiaGou

Add To Cart

jiaGou

Buy Now

masterCard
visa
jcb
americanExpress
shop_b
Global Patient Derived Xenograft & PDX Models Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Patient Derived Xenograft & PDX Models Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 100

Published Date: 02 Jan 2023

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description

arrow-d3
btl

Description

Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. PDX models are used to create an environment that allows for the natural growth of cancer, its monitoring, and corresponding treatment evaluations for the original patient.

According to our (Global Info Research) latest study, the global Patient Derived Xenograft & PDX Models market size was valued at USD 341.2 million in 2022 and is forecast to a readjusted size of USD 589.9 million by 2029 with a CAGR of 8.1% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.

This report is a detailed and comprehensive analysis for global Patient Derived Xenograft & PDX Models market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Patient Derived Xenograft & PDX Models market size and forecasts, in consumption value ($ Million), 2018-2029
Global Patient Derived Xenograft & PDX Models market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Patient Derived Xenograft & PDX Models market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Patient Derived Xenograft & PDX Models market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Patient Derived Xenograft & PDX Models
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Patient Derived Xenograft & PDX Models market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Crown Bioscience, The Jackson Laboratory, Champions Oncology, Charles River Laboratories and WuXi Apptec, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Patient Derived Xenograft & PDX Models market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Mice Models
Rat Models

Market segment by Application
Pre-clinical Drug Development and Basic Cancer Research
Biomarker Analysis

Market segment by players, this report covers
Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Patient Derived Xenograft & PDX Models product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Patient Derived Xenograft & PDX Models, with revenue, gross margin and global market share of Patient Derived Xenograft & PDX Models from 2018 to 2023.
Chapter 3, the Patient Derived Xenograft & PDX Models competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Patient Derived Xenograft & PDX Models market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Patient Derived Xenograft & PDX Models.
Chapter 13, to describe Patient Derived Xenograft & PDX Models research findings and conclusion.
btl

Table of Contents

1 Market Overview
1.1 Product Overview and Scope of Patient Derived Xenograft & PDX Models
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Patient Derived Xenograft & PDX Models by Type
1.3.1 Overview: Global Patient Derived Xenograft & PDX Models Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Patient Derived Xenograft & PDX Models Consumption Value Market Share by Type in 2022
1.3.3 Mice Models
1.3.4 Rat Models
1.4 Global Patient Derived Xenograft & PDX Models Market by Application
1.4.1 Overview: Global Patient Derived Xenograft & PDX Models Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Pre-clinical Drug Development and Basic Cancer Research
1.4.3 Biomarker Analysis
1.5 Global Patient Derived Xenograft & PDX Models Market Size & Forecast
1.6 Global Patient Derived Xenograft & PDX Models Market Size and Forecast by Region
1.6.1 Global Patient Derived Xenograft & PDX Models Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Patient Derived Xenograft & PDX Models Market Size by Region, (2018-2029)
1.6.3 North America Patient Derived Xenograft & PDX Models Market Size and Prospect (2018-2029)
1.6.4 Europe Patient Derived Xenograft & PDX Models Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Patient Derived Xenograft & PDX Models Market Size and Prospect (2018-2029)
1.6.6 South America Patient Derived Xenograft & PDX Models Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Patient Derived Xenograft & PDX Models Market Size and Prospect (2018-2029)

2 Company Profiles
2.1 Crown Bioscience
2.1.1 Crown Bioscience Details
2.1.2 Crown Bioscience Major Business
2.1.3 Crown Bioscience Patient Derived Xenograft & PDX Models Product and Solutions
2.1.4 Crown Bioscience Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Crown Bioscience Recent Developments and Future Plans
2.2 The Jackson Laboratory
2.2.1 The Jackson Laboratory Details
2.2.2 The Jackson Laboratory Major Business
2.2.3 The Jackson Laboratory Patient Derived Xenograft & PDX Models Product and Solutions
2.2.4 The Jackson Laboratory Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 The Jackson Laboratory Recent Developments and Future Plans
2.3 Champions Oncology
2.3.1 Champions Oncology Details
2.3.2 Champions Oncology Major Business
2.3.3 Champions Oncology Patient Derived Xenograft & PDX Models Product and Solutions
2.3.4 Champions Oncology Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Champions Oncology Recent Developments and Future Plans
2.4 Charles River Laboratories
2.4.1 Charles River Laboratories Details
2.4.2 Charles River Laboratories Major Business
2.4.3 Charles River Laboratories Patient Derived Xenograft & PDX Models Product and Solutions
2.4.4 Charles River Laboratories Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Charles River Laboratories Recent Developments and Future Plans
2.5 WuXi Apptec
2.5.1 WuXi Apptec Details
2.5.2 WuXi Apptec Major Business
2.5.3 WuXi Apptec Patient Derived Xenograft & PDX Models Product and Solutions
2.5.4 WuXi Apptec Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 WuXi Apptec Recent Developments and Future Plans
2.6 Oncodesign
2.6.1 Oncodesign Details
2.6.2 Oncodesign Major Business
2.6.3 Oncodesign Patient Derived Xenograft & PDX Models Product and Solutions
2.6.4 Oncodesign Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Oncodesign Recent Developments and Future Plans
2.7 Horizon Discovery
2.7.1 Horizon Discovery Details
2.7.2 Horizon Discovery Major Business
2.7.3 Horizon Discovery Patient Derived Xenograft & PDX Models Product and Solutions
2.7.4 Horizon Discovery Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Horizon Discovery Recent Developments and Future Plans
2.8 Pharmatest Services
2.8.1 Pharmatest Services Details
2.8.2 Pharmatest Services Major Business
2.8.3 Pharmatest Services Patient Derived Xenograft & PDX Models Product and Solutions
2.8.4 Pharmatest Services Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Pharmatest Services Recent Developments and Future Plans
2.9 Hera Biolabs
2.9.1 Hera Biolabs Details
2.9.2 Hera Biolabs Major Business
2.9.3 Hera Biolabs Patient Derived Xenograft & PDX Models Product and Solutions
2.9.4 Hera Biolabs Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Hera Biolabs Recent Developments and Future Plans
2.10 EPO Berlin-Buch
2.10.1 EPO Berlin-Buch Details
2.10.2 EPO Berlin-Buch Major Business
2.10.3 EPO Berlin-Buch Patient Derived Xenograft & PDX Models Product and Solutions
2.10.4 EPO Berlin-Buch Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 EPO Berlin-Buch Recent Developments and Future Plans
2.11 Xentech
2.11.1 Xentech Details
2.11.2 Xentech Major Business
2.11.3 Xentech Patient Derived Xenograft & PDX Models Product and Solutions
2.11.4 Xentech Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Xentech Recent Developments and Future Plans
2.12 Urolead
2.12.1 Urolead Details
2.12.2 Urolead Major Business
2.12.3 Urolead Patient Derived Xenograft & PDX Models Product and Solutions
2.12.4 Urolead Patient Derived Xenograft & PDX Models Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Urolead Recent Developments and Future Plans

3 Market Competition, by Players
3.1 Global Patient Derived Xenograft & PDX Models Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Patient Derived Xenograft & PDX Models by Company Revenue
3.2.2 Top 3 Patient Derived Xenograft & PDX Models Players Market Share in 2022
3.2.3 Top 6 Patient Derived Xenograft & PDX Models Players Market Share in 2022
3.3 Patient Derived Xenograft & PDX Models Market: Overall Company Footprint Analysis
3.3.1 Patient Derived Xenograft & PDX Models Market: Region Footprint
3.3.2 Patient Derived Xenograft & PDX Models Market: Company Product Type Footprint
3.3.3 Patient Derived Xenograft & PDX Models Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
4.1 Global Patient Derived Xenograft & PDX Models Consumption Value and Market Share by Type (2018-2023)
4.2 Global Patient Derived Xenograft & PDX Models Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
5.1 Global Patient Derived Xenograft & PDX Models Consumption Value Market Share by Application (2018-2023)
5.2 Global Patient Derived Xenograft & PDX Models Market Forecast by Application (2024-2029)

6 North America
6.1 North America Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2029)
6.2 North America Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2029)
6.3 North America Patient Derived Xenograft & PDX Models Market Size by Country
6.3.1 North America Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2029)
6.3.2 United States Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
6.3.3 Canada Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
6.3.4 Mexico Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)

7 Europe
7.1 Europe Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2029)
7.2 Europe Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2029)
7.3 Europe Patient Derived Xenograft & PDX Models Market Size by Country
7.3.1 Europe Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2029)
7.3.2 Germany Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
7.3.3 France Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
7.3.5 Russia Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
7.3.6 Italy Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)

8 Asia-Pacific
8.1 Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Patient Derived Xenograft & PDX Models Market Size by Region
8.3.1 Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Region (2018-2029)
8.3.2 China Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
8.3.3 Japan Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
8.3.4 South Korea Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
8.3.5 India Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
8.3.7 Australia Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)

9 South America
9.1 South America Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2029)
9.2 South America Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2029)
9.3 South America Patient Derived Xenograft & PDX Models Market Size by Country
9.3.1 South America Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2029)
9.3.2 Brazil Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
9.3.3 Argentina Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)

10 Middle East & Africa
10.1 Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Patient Derived Xenograft & PDX Models Market Size by Country
10.3.1 Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2029)
10.3.2 Turkey Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)
10.3.4 UAE Patient Derived Xenograft & PDX Models Market Size and Forecast (2018-2029)

11 Market Dynamics
11.1 Patient Derived Xenograft & PDX Models Market Drivers
11.2 Patient Derived Xenograft & PDX Models Market Restraints
11.3 Patient Derived Xenograft & PDX Models Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
12.1 Patient Derived Xenograft & PDX Models Industry Chain
12.2 Patient Derived Xenograft & PDX Models Upstream Analysis
12.3 Patient Derived Xenograft & PDX Models Midstream Analysis
12.4 Patient Derived Xenograft & PDX Models Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. Global Patient Derived Xenograft & PDX Models Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Patient Derived Xenograft & PDX Models Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Patient Derived Xenograft & PDX Models Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Patient Derived Xenograft & PDX Models Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Crown Bioscience Company Information, Head Office, and Major Competitors
Table 6. Crown Bioscience Major Business
Table 7. Crown Bioscience Patient Derived Xenograft & PDX Models Product and Solutions
Table 8. Crown Bioscience Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Crown Bioscience Recent Developments and Future Plans
Table 10. The Jackson Laboratory Company Information, Head Office, and Major Competitors
Table 11. The Jackson Laboratory Major Business
Table 12. The Jackson Laboratory Patient Derived Xenograft & PDX Models Product and Solutions
Table 13. The Jackson Laboratory Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. The Jackson Laboratory Recent Developments and Future Plans
Table 15. Champions Oncology Company Information, Head Office, and Major Competitors
Table 16. Champions Oncology Major Business
Table 17. Champions Oncology Patient Derived Xenograft & PDX Models Product and Solutions
Table 18. Champions Oncology Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Champions Oncology Recent Developments and Future Plans
Table 20. Charles River Laboratories Company Information, Head Office, and Major Competitors
Table 21. Charles River Laboratories Major Business
Table 22. Charles River Laboratories Patient Derived Xenograft & PDX Models Product and Solutions
Table 23. Charles River Laboratories Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Charles River Laboratories Recent Developments and Future Plans
Table 25. WuXi Apptec Company Information, Head Office, and Major Competitors
Table 26. WuXi Apptec Major Business
Table 27. WuXi Apptec Patient Derived Xenograft & PDX Models Product and Solutions
Table 28. WuXi Apptec Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. WuXi Apptec Recent Developments and Future Plans
Table 30. Oncodesign Company Information, Head Office, and Major Competitors
Table 31. Oncodesign Major Business
Table 32. Oncodesign Patient Derived Xenograft & PDX Models Product and Solutions
Table 33. Oncodesign Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Oncodesign Recent Developments and Future Plans
Table 35. Horizon Discovery Company Information, Head Office, and Major Competitors
Table 36. Horizon Discovery Major Business
Table 37. Horizon Discovery Patient Derived Xenograft & PDX Models Product and Solutions
Table 38. Horizon Discovery Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Horizon Discovery Recent Developments and Future Plans
Table 40. Pharmatest Services Company Information, Head Office, and Major Competitors
Table 41. Pharmatest Services Major Business
Table 42. Pharmatest Services Patient Derived Xenograft & PDX Models Product and Solutions
Table 43. Pharmatest Services Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Pharmatest Services Recent Developments and Future Plans
Table 45. Hera Biolabs Company Information, Head Office, and Major Competitors
Table 46. Hera Biolabs Major Business
Table 47. Hera Biolabs Patient Derived Xenograft & PDX Models Product and Solutions
Table 48. Hera Biolabs Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Hera Biolabs Recent Developments and Future Plans
Table 50. EPO Berlin-Buch Company Information, Head Office, and Major Competitors
Table 51. EPO Berlin-Buch Major Business
Table 52. EPO Berlin-Buch Patient Derived Xenograft & PDX Models Product and Solutions
Table 53. EPO Berlin-Buch Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. EPO Berlin-Buch Recent Developments and Future Plans
Table 55. Xentech Company Information, Head Office, and Major Competitors
Table 56. Xentech Major Business
Table 57. Xentech Patient Derived Xenograft & PDX Models Product and Solutions
Table 58. Xentech Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Xentech Recent Developments and Future Plans
Table 60. Urolead Company Information, Head Office, and Major Competitors
Table 61. Urolead Major Business
Table 62. Urolead Patient Derived Xenograft & PDX Models Product and Solutions
Table 63. Urolead Patient Derived Xenograft & PDX Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Urolead Recent Developments and Future Plans
Table 65. Global Patient Derived Xenograft & PDX Models Revenue (USD Million) by Players (2018-2023)
Table 66. Global Patient Derived Xenograft & PDX Models Revenue Share by Players (2018-2023)
Table 67. Breakdown of Patient Derived Xenograft & PDX Models by Company Type (Tier 1, Tier 2, and Tier 3)
Table 68. Market Position of Players in Patient Derived Xenograft & PDX Models, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 69. Head Office of Key Patient Derived Xenograft & PDX Models Players
Table 70. Patient Derived Xenograft & PDX Models Market: Company Product Type Footprint
Table 71. Patient Derived Xenograft & PDX Models Market: Company Product Application Footprint
Table 72. Patient Derived Xenograft & PDX Models New Market Entrants and Barriers to Market Entry
Table 73. Patient Derived Xenograft & PDX Models Mergers, Acquisition, Agreements, and Collaborations
Table 74. Global Patient Derived Xenograft & PDX Models Consumption Value (USD Million) by Type (2018-2023)
Table 75. Global Patient Derived Xenograft & PDX Models Consumption Value Share by Type (2018-2023)
Table 76. Global Patient Derived Xenograft & PDX Models Consumption Value Forecast by Type (2024-2029)
Table 77. Global Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2023)
Table 78. Global Patient Derived Xenograft & PDX Models Consumption Value Forecast by Application (2024-2029)
Table 79. North America Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2023) & (USD Million)
Table 80. North America Patient Derived Xenograft & PDX Models Consumption Value by Type (2024-2029) & (USD Million)
Table 81. North America Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2023) & (USD Million)
Table 82. North America Patient Derived Xenograft & PDX Models Consumption Value by Application (2024-2029) & (USD Million)
Table 83. North America Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2023) & (USD Million)
Table 84. North America Patient Derived Xenograft & PDX Models Consumption Value by Country (2024-2029) & (USD Million)
Table 85. Europe Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2023) & (USD Million)
Table 86. Europe Patient Derived Xenograft & PDX Models Consumption Value by Type (2024-2029) & (USD Million)
Table 87. Europe Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2023) & (USD Million)
Table 88. Europe Patient Derived Xenograft & PDX Models Consumption Value by Application (2024-2029) & (USD Million)
Table 89. Europe Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Patient Derived Xenograft & PDX Models Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2023) & (USD Million)
Table 92. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Type (2024-2029) & (USD Million)
Table 93. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2023) & (USD Million)
Table 94. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Application (2024-2029) & (USD Million)
Table 95. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Region (2018-2023) & (USD Million)
Table 96. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value by Region (2024-2029) & (USD Million)
Table 97. South America Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2023) & (USD Million)
Table 98. South America Patient Derived Xenograft & PDX Models Consumption Value by Type (2024-2029) & (USD Million)
Table 99. South America Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2023) & (USD Million)
Table 100. South America Patient Derived Xenograft & PDX Models Consumption Value by Application (2024-2029) & (USD Million)
Table 101. South America Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2023) & (USD Million)
Table 102. South America Patient Derived Xenograft & PDX Models Consumption Value by Country (2024-2029) & (USD Million)
Table 103. Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Type (2018-2023) & (USD Million)
Table 104. Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Type (2024-2029) & (USD Million)
Table 105. Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Application (2018-2023) & (USD Million)
Table 106. Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Application (2024-2029) & (USD Million)
Table 107. Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Country (2018-2023) & (USD Million)
Table 108. Middle East & Africa Patient Derived Xenograft & PDX Models Consumption Value by Country (2024-2029) & (USD Million)
Table 109. Patient Derived Xenograft & PDX Models Raw Material
Table 110. Key Suppliers of Patient Derived Xenograft & PDX Models Raw Materials
List of Figures
Figure 1. Patient Derived Xenograft & PDX Models Picture
Figure 2. Global Patient Derived Xenograft & PDX Models Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Patient Derived Xenograft & PDX Models Consumption Value Market Share by Type in 2022
Figure 4. Mice Models
Figure 5. Rat Models
Figure 6. Global Patient Derived Xenograft & PDX Models Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Patient Derived Xenograft & PDX Models Consumption Value Market Share by Application in 2022
Figure 8. Pre-clinical Drug Development and Basic Cancer Research Picture
Figure 9. Biomarker Analysis Picture
Figure 10. Global Patient Derived Xenograft & PDX Models Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Patient Derived Xenograft & PDX Models Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Market Patient Derived Xenograft & PDX Models Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 13. Global Patient Derived Xenograft & PDX Models Consumption Value Market Share by Region (2018-2029)
Figure 14. Global Patient Derived Xenograft & PDX Models Consumption Value Market Share by Region in 2022
Figure 15. North America Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 16. Europe Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 17. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 18. South America Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 19. Middle East and Africa Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 20. Global Patient Derived Xenograft & PDX Models Revenue Share by Players in 2022
Figure 21. Patient Derived Xenograft & PDX Models Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 22. Global Top 3 Players Patient Derived Xenograft & PDX Models Market Share in 2022
Figure 23. Global Top 6 Players Patient Derived Xenograft & PDX Models Market Share in 2022
Figure 24. Global Patient Derived Xenograft & PDX Models Consumption Value Share by Type (2018-2023)
Figure 25. Global Patient Derived Xenograft & PDX Models Market Share Forecast by Type (2024-2029)
Figure 26. Global Patient Derived Xenograft & PDX Models Consumption Value Share by Application (2018-2023)
Figure 27. Global Patient Derived Xenograft & PDX Models Market Share Forecast by Application (2024-2029)
Figure 28. North America Patient Derived Xenograft & PDX Models Consumption Value Market Share by Type (2018-2029)
Figure 29. North America Patient Derived Xenograft & PDX Models Consumption Value Market Share by Application (2018-2029)
Figure 30. North America Patient Derived Xenograft & PDX Models Consumption Value Market Share by Country (2018-2029)
Figure 31. United States Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 32. Canada Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 33. Mexico Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 34. Europe Patient Derived Xenograft & PDX Models Consumption Value Market Share by Type (2018-2029)
Figure 35. Europe Patient Derived Xenograft & PDX Models Consumption Value Market Share by Application (2018-2029)
Figure 36. Europe Patient Derived Xenograft & PDX Models Consumption Value Market Share by Country (2018-2029)
Figure 37. Germany Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 38. France Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 39. United Kingdom Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 40. Russia Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 41. Italy Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 42. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value Market Share by Type (2018-2029)
Figure 43. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value Market Share by Application (2018-2029)
Figure 44. Asia-Pacific Patient Derived Xenograft & PDX Models Consumption Value Market Share by Region (2018-2029)
Figure 45. China Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 46. Japan Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 47. South Korea Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 48. India Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 49. Southeast Asia Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 50. Australia Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 51. South America Patient Derived Xenograft & PDX Models Consumption Value Market Share by Type (2018-2029)
Figure 52. South America Patient Derived Xenograft & PDX Models Consumption Value Market Share by Application (2018-2029)
Figure 53. South America Patient Derived Xenograft & PDX Models Consumption Value Market Share by Country (2018-2029)
Figure 54. Brazil Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 55. Argentina Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 56. Middle East and Africa Patient Derived Xenograft & PDX Models Consumption Value Market Share by Type (2018-2029)
Figure 57. Middle East and Africa Patient Derived Xenograft & PDX Models Consumption Value Market Share by Application (2018-2029)
Figure 58. Middle East and Africa Patient Derived Xenograft & PDX Models Consumption Value Market Share by Country (2018-2029)
Figure 59. Turkey Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 60. Saudi Arabia Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 61. UAE Patient Derived Xenograft & PDX Models Consumption Value (2018-2029) & (USD Million)
Figure 62. Patient Derived Xenograft & PDX Models Market Drivers
Figure 63. Patient Derived Xenograft & PDX Models Market Restraints
Figure 64. Patient Derived Xenograft & PDX Models Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Patient Derived Xenograft & PDX Models in 2022
Figure 67. Manufacturing Process Analysis of Patient Derived Xenograft & PDX Models
Figure 68. Patient Derived Xenograft & PDX Models Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Discussion of all the project requirements and queries

Validation and triangulation of secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

btl

Companies Mentioned

Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead
jiaGou

Add To Cart

gouMai

Buy Now